Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
Moreau, Philippe (University Hospital Hôtel-Dieu)
Van De Donk, Niels WCJ (Department of Hematology. Amsterdam University Medical Center)
Nahi, Hareth (Karolinska University Hospital and Karolinska Institutet (Suècia))
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Nooka, Ajay K (Winship Cancer Institute. Emory University)
Martin, Thomas (University of California San Francisco)
Rosinol, Laura (Hospital Clínic i Provincial de Barcelona)
Karlin, Lionel (Centre Hospitalier Lyon Sud)
Benboubker, Lotfi (Hôpital Bretonneau)
Mateos, Maria-Victoria (University Hospital de Salamanca)
Popat, Rakesh (University College London Hospitals)
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid))
Sidana, Surbhi (Stanford University of Medicine)
Delforge, Michele (University of Leuven)
Pei, Lixia (Janssen Research & Development)
Trancucci, Danielle (Janssen Research & Development)
Olyslager, Yunsi (Janssen Research & Development)
Uhlar, Clarissa (Janssen Research & Development)
Stephenson, Tara (Janssen Research & Development)
Rampelbergh, Rian Van (Janssen Research & Development)
Banerjee, Arnob (Janssen Research & Development)
Kobos, Rachel (Janssen Research & Development)
Usmani, Saad Z (Levine Cancer Institute-Atrium Health)

Fecha:	2023
Resumen:	What is this summary about? This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. Most participants who took part in the study had at least 3 prior treatments for multiple myeloma before their cancer came back. How was the study in this summary conducted? A total of 165 participants from 9 countries were included in this study. All participants were given teclistamab once per week and monitored for side effects. Once participants started taking teclistamab, they were checked regularly to monitor if their cancer had no change, improved (responded to treatment), or worsened or spread (known as disease progression). What were the results of the study? After approximately 14. 1 months of follow-up (from 2020 to 2021), 63% of participants who were given teclistamab had a decrease in myeloma burden, meaning that they responded to treatment with teclistamab. Participants who responded to teclistamab lived without their myeloma coming back for approximately 18. 4 months. The most common side effects were infections, cytokine release syndrome, abnormally low white and red blood cell counts (neutropenia, lymphopenia, and anemia), and low platelet cell counts (thrombocytopenia). Approximately 65% of participants experienced serious side effects. What do the results of this study mean? Overall, more than half of the participants (63%) in the MajesTEC-1 study responded to treatment with teclistamab despite previous myeloma treatment failures. Clinical Trial Registration: NCT03145181, NCT04557098 (ClinicalTrials. gov) </sec.
Nota:	The authors acknowledge the patients and investigators who participated in this study, in addition to the staff members at the study sites, the Data Review and Safety Monitoring Committees, Alliance Foundation Trials (AFT; https://acknowledgments.alliancefound.org), and the Janssen Team. This work was funded by Janssen Oncology. The MajesTEC-1 study was sponsored by Janssen Oncology and designed in partnership with AFT. Editorial and medical writing support were provided by Carolyn Farnsworth, Katie Yoest, PhD, and Katie Veleta, PhD, of MedThink SciCom and were funded by Janssen Global Services, LLC. Financial & competing interests disclosure
Nota:	The authors' full disclosure information can be found in the original research article. Writing support for this summary was provided under the direction of the author(s) by Katie Yoest, PhD, and Katie Veleta, PhD, of MedThink SciCom and was funded by Janssen Research and Development. Open access
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Ressenya ; recerca ; Versió publicada
Publicado en:	Future oncology (London, England), Vol. 19 Núm. 12 (january 2023) , p. 811-818, ISSN 1744-8301

DOI: 10.2217/fon-2023-0171

8 p, 1.0 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Instituto de Investigación contra la Leucemia Josep Carreras
Artículos > Artículos de investigación
Artículos > Artículos publicados
Artículos > Reseñas